Earlier this year an influenza virus animation spread on YouTube just after the emergence of swine-origin influenza H1N1. I invited readers to criticise the animation which contained several errors. A much better depiction of influenza virus animation has been created by XVIVO. It’s not only more beautifully rendered, but is scientifically much more accurate. A …
A reader of the post “Severe cases of pandemic influenza” asked whether I could comment on an article in The Atlantic which questions the efficacy of the influenza vaccine in the elderly population. I passed the request on to Revere at Effect Measure who wrote an excellent and thoughtful response, “Journalists sink in The Atlantic …
Xenotropic murine leukemia virus-like virus (XMRV) was discovered in 2006 during a search for viral sequences in prostate cancer tissues. The results of a recent study revealed that the virus is present in 23% of prostate cancers from patients in the US. Understanding the role of XMRV in prostate cancers requires more extensive epidemiological studies, …
The influenza A (H1N1) 2009 vaccine produced by GlaxoSmithKline has been approved by Canada Health. Here is some information on the vaccine to supplement what I’ve provided about the US counterparts. The Canadian vaccine, called Arepanrix H1N1, is supplied in two parts. One contains inactivated H1N1 influenza virus, and the second consists of AS03 adjuvant …
The World Health Organization recently convened a meeting of 100 clinicians, scientists, and public health professionals to discuss the clinical features of pandemic influenza. They concluded that the vast majority of infections with the 2009 H1N1 influenza virus were uncomplicated and are followed by full recovery within 7 days. However, some patients, including children, develop …
There have been many interesting responses to my recent post, “Are you receiving the influenza 2009 H1N1 vaccine?” Some individuals have already been immunized or plan to do so shortly. Others are concerned about the safety and efficacy of the monovalent preparations. As pointed out recently in a Nature editorial, “Mass-vaccination campaigns…must take public concerns …
Influenza A (H1N1) 2009 vaccine: efficacy and safety Read More »
